Clinical Trial Update: Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IMC-A12 (cixutumumab) with or without cetuximab in metastatic colorectal cancer after prior anti-EGFR therapy; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IMC-A12 (cixutumumab) (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-06